论文部分内容阅读
目的:探讨羟苯磺酸钙对治疗慢性肾功能衰竭的疗效。方法:选取2015年8月至2016年8月在慈溪市人民医院接受治疗的慢性肾功能衰竭患者120例,采用随机的方法将所有的入选患者分为观察组和对照组各60例,其中对照组患者给予常规治疗,观察组患者给予羟苯磺酸钙治疗,比较两组患者治疗后的临床疗效、BUN、SCr、Ccr、血红蛋白、24h尿蛋白以及尿红细胞变化情况。结果:与治疗前比较,两组患者的BUN、SCr都有所下降,观察组(14.12±3.89mmol/L、225.26±31.25umol/L)低于对照组(17.29±4.02mmol/L、326.12±44.02umol/L),两组比较差异显著(P<0.05);治疗后,两组患者的Ccr都有所上升,观察组(26.35±3.24ml/min)高于对照组(17.62±3.02ml/min),两组比较差异显著(P<0.05);治疗后,24h尿蛋白以及尿红细胞都有所下降,观察组(1.03±0.32g、10.23±2.13个)低于对照组(1.59±0.39g、15.29±3.89个),差异显著(P<0.05);两组患者的血红蛋白都有所上升,观察组(85.12±6.78g/L)高于对照组(80.36±5.89g/L),差异显著(P<0.05);观察组治疗后的总有效率为95.00%高于对照组68.33%,两组比较差异显著(P<0.05)。结论:羟苯磺酸钙治疗肾功能衰竭患者,对患者的肾功能具有保护作用,临床效果显著。
Objective: To investigate the efficacy of calcium dobesilate in the treatment of chronic renal failure. Methods: A total of 120 patients with chronic renal failure who were treated in Cixi People’s Hospital from August 2015 to August 2016 were selected. All patients were divided into observation group and control group with 60 cases in each group randomly. Patients in the observation group were treated with calcium dobesilate. The clinical efficacy, BUN, SCr, Ccr, hemoglobin, 24h urinary protein and urinary erythrocytes were compared between the two groups after treatment. Results: The BUN and SCr in both groups decreased compared with those before treatment. The levels of BUN and SCr in the observation group (14.12 ± 3.89mmol / L, 225.26 ± 31.25umol / L) were lower than those in the control group (17.29 ± 4.02mmol / L, 326.12 ± 44.02umol / L), there was significant difference between the two groups (P <0.05). After treatment, the Ccr of both groups increased, the observation group (26.35 ± 3.24ml / min) was higher than the control group (17.62 ± 3.02ml / min, the difference between the two groups was significant (P <0.05). After treatment, the levels of urinary protein and urinary erythrocytes decreased in 24 hours (1.03 ± 0.32g, 10.23 ± 2.13) compared with the control group (1.59 ± 0.39g , 15.29 ± 3.89, respectively), the difference was significant (P <0.05); the hemoglobin of both groups increased, the difference was significant between the observation group (85.12 ± 6.78g / L) and the control group (80.36 ± 5.89g / L) (P <0.05). The total effective rate of the observation group after treatment was 95.00%, which was significantly higher than that of the control group (68.33%). There was significant difference between the two groups (P <0.05). Conclusion: Calcium dobesilate in the treatment of renal failure patients with renal function has a protective effect, the clinical effect is significant.